Literature DB >> 22213236

Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance.

Andreas Karakatsanis1, Ioannis Papaconstantinou, Maria Gazouli, Anna Lyberopoulou, George Polymeneas, Dionysios Voros.   

Abstract

MicroRNAs are a class of non-coding molecules found to regulate a variety of cellular functions in health and disease. Dysregulation of microRNAs is involved in liver disease, especially hepatocarcinogenesis. Since primary hepatic malignancies are typically characterized by late diagnosis, frequent recurrence, and poor response to adjuvant therapy, there is a need for the discovery of novel biomarkers in order to achieve earlier diagnosis, predict tumor aggressiveness and response to adjuvant therapy. The purpose of this study is to evaluate the expression of certain microRNAs (miR-21, -31, -122, -145, -146a, - 200c, -221, -222 and -223) in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), as well as to assess their prognostic significance. Micro-RNA expression was assessed by reverse transcription and real-time PCR (RT-PCR). Clinicopathological data and survival rates were retrieved and analyzed. According to our results, miR-21, miR-31, miR-122, miR-221, miR-222 were significantly up-regulated in HCC tissues, whereas miR-145, miR-146a, miR-200c, and miR-223 were found to be down-regulated. Concerning ICC samples, miR-21, miR-31, and miR-223 were found to be over-expressed, whereas miR-122, miR-145, miR-200c, miR-221, and miR-222 were down-regulated. Additionally, expression of miR-21, miR-31, miR-122, and miR-221 in HCC correlated with cirrhosis, while miR-21 and miR-221 associated with tumor stage and poor prognosis. In ICC tissues, miR-21, miR-31, and miR-223 were found to be over-expressed, but no correlation with clinicopathological features was found.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22213236     DOI: 10.1002/mc.21864

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  152 in total

1.  Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.

Authors:  Zehra Oksuz; Mehmet Sami Serin; Engin Kaplan; Aylin Dogen; Seda Tezcan; Gonul Aslan; Gurol Emekdas; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

3.  Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies.

Authors:  Alessia Piluso; Laura Gragnani; Elisa Fognani; Elena Grandini; Monica Monti; Cristina Stasi; Elisabetta Loggi; Marzia Margotti; Fabio Conti; Pietro Andreone; Anna Linda Zignego
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

Review 4.  Epigenetics of hepatocellular carcinoma: role of microRNA.

Authors:  Sharad Khare; Qiong Zhang; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

5.  Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats.

Authors:  Egle Juskeviciute; Rachael P Dippold; Anil N Antony; Aditi Swarup; Rajanikanth Vadigepalli; Jan B Hoek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-15       Impact factor: 4.052

6.  The effect of recombinant lentiviral vector encoding miR-145 on human esophageal cancer cells.

Authors:  Tian-Yun Wang; Qing-Qing Zhang; Xi Zhang; Qiu-Li Sun; Chun-Peng Zhao; Xiao-Yin Wang
Journal:  Tumour Biol       Date:  2015-07-09

Review 7.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

8.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

9.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

10.  Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats.

Authors:  Merricka C Livingstone; Natalie M Johnson; Bill D Roebuck; Thomas W Kensler; John D Groopman
Journal:  Mol Carcinog       Date:  2019-08-02       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.